SGLT2 Inhibitors and Perioperative Period

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-01

Study Completion Date

2025-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcomes With Tight Control of Hyperglycemia in Cardiac Surgery Patients

NCT00282698

Cardiac Surgical Procedures Hyperglycemia

COMPLETED PHASE3

Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial

NCT05314725

Postoperative Hyperglycemia Stress Hyperglycemia

UNKNOWN PHASE2

Diabetes in the Perioperative Period

NCT00738114

Hyperglycemia Diabetes

COMPLETED

Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery

NCT00328094

Peripheral Vascular Disease Abdominal Aortic Aneurysm

TERMINATED NA

Comparing Blood Glucose Control Intraoperative Between Insulin Drip vs. Insulin Boluses Will Provide Valuable Information on the Optimal Method for Achieving Blood Glucose Control Intraoperatively.

NCT07056088

Hypoglycemia (Diabetic)

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With over 50 million cases of heart failure worldwide, heart failure is one of the most serious health issues facing humanity. Heart failure patients still have an extremely poor prognosis and quality of life, even with advancements in heart failure treatment. It continues to be the most common cause of hospitalization in elderly.

A substantial number of theories have been proposed to explain the beneficial effects of SGLT2 inhibitors. These include blood pressure lowering, increasing diuresis/natriuresis, improving cardiac energy metabolism, preventing inflammation, weight loss, improving glucose control, inhibiting the sympathetic nervous system, preventing adverse cardiac remodeling, preventing ischemia/reperfusion injury, inhibiting the cardiac Na/H exchanger inhibiting SGLT1, reducing hyperuricemia, increasing autophagy and lysosomal degradation, decreasing epicardial fat mass, increasing erythropoietin (EPO) levels, increasing circulating provascular progenitor cells, decreasing oxidative stress; and improving vascular function.

In addition to lowering blood sugar, several large trials also have demonstrated cardiovascular and renal benefits in patients with T2DM. Surprisingly, recent data also suggest that SGLT-2 inhibitors may improve cardiovascular and renal outcomes in patients without diabetes, leading to expanded indications for their use.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Perioperative Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SGLT2 group

First group will receive SGLT2 (Dapaglifozin or Empagliflozin) inhibitors one month before surgery and three months after surgery.

SGLT2 inhibitor

Intervention Type DRUG

Dapagliflozin 10 mg or Empagliflozin 25mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SGLT2 inhibitor

Dapagliflozin 10 mg or Empagliflozin 25mg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dapagliflozin and Empagliflozin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. All subjects with coronary artery disease or valvular heart disease referred to cardiac surgery

Exclusion Criteria

1. Congenital heart disease.
2. Cardiomyopathy (EF\>40%).
3. Sever renal impairment (eGFR\>30).
4. COPD.
5. Marked obesity (BMI\<35).
6. Previous cardiac surgery.

Eligible Sex

ALL

Accepts Healthy Volunteers

No